Flowsion

Flowsion is a Denmark-based medical device company focused on automated blood glucose monitoring and control for intensive care unit patients. Its lead product platform, Glycostat, is an intravenous continuous glucose monitoring and control system intended to support tight glycemic control in critically ill patients. The company has described the technology as combining continuous glucose sensing with an algorithm for automated blood glucose control in the hospital setting. Flowsion received CE mark approval for Glycostat in 2021, positioning the company as a commercial-stage critical care device developer in Europe. Earlier company materials also refer to the underlying system as Diramo, which appears to be the precursor or core system behind the Glycostat product family.